Key facts
- This page summarizes Adam King's Form 4 filing for QSAM Biosciences, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Jun 2023, 06:14.
Adam King - 03 Mar 2022 Form 4 Insider Report for QSAM Biosciences, Inc.
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 03 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Jun 2023, 06:14:22 UTC
- Next SEC filing
- 02 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adam King
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Adam King filed Form 4 for QSAM Biosciences, Inc. on 29 Jun 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
QSAM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,910
- Change %
- Price
- $0.000000
- Shares after
- 20,910
- Date
- 23 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
QSAM
transaction
Common Stock
Award
- Transaction value
- Shares
- +2,040
- Change %
- +9.8%
- Price
- Shares after
- 22,950
- Date
- 23 Jun 2023
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
QSAM
transaction
Derivative
Options to buy common stock
Award
- Transaction value
- $0
- Shares
- +12,500
- Change %
- Price
- $0.000000
- Shares after
- 12,500
- Date
- 03 Mar 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,500
- Exercise price
- $10.00
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This award of shares is being made pursuant to the Issuer's restricted stock award agreement and is subject to a vesting schedule, such that a portion or all of this award of restricted stock may be forfeited in the future if certain milestones are not met.
Footnote F2
Shares acquired upon conversion of deferred salary of $10,200.
Footnote F3
As of 3/31/2023, 9,375 shares vested based on performance. The balance of the shares will vest in 36 monthly installments commencing March 1, 2023.